Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 24, Issue 2, pp 85–91 | Cite as

Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28

  • Dalton S. McLean
  • Marc S. Sabatine
  • Wei Guo
  • Carolyn H. McCabe
  • Christopher P. CannonEmail author
Article

Abstract

The Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28) trial was a randomized, double-blind, placebo-controlled study of clopidogrel in 3,491 patients receiving fibrinolytic therapy for ST-segment elevation myocardial infarction. Patients were randomized to clopidogrel or placebo begun at the time of fibrinolysis. This analysis reports the outcomes among the 136 patients in the trial population who underwent coronary artery bypass grafting (CABG) during the index hospitalization. There was no difference in the rates of TIMI major or minor bleeding between the clopidogrel and placebo groups from randomization to the end of follow-up (13.6% vs. 14.3%, P = 1.0) or from the time of CABG to the end of follow-up (9.1% vs. 11.4%, P = 0.78). When any day for study medication discontinuation ≤5 days prior to CABG was chosen as a cut point to evaluate bleeding risk for clopidogrel vs. placebo, there was no excess bleeding in the clopidogrel group. Among patients undergoing CABG, there was a trend toward reduction in the risk of cardiovascular death, recurrent MI, or recurrent ischemia requiring urgent revascularization at 30 days for those taking clopidogrel (OR 0.66, 95% CI 0.27–1.5; P = 0.37), consistent with the benefit seen in the overall trial population (OR 0.80, CI 0.65–0.97; P = 0.03). In conclusion, early clopidogrel treatment among CLARITY-TIMI 28 patients undergoing CABG was not associated with an increase in the rate of peri-operative bleeding and showed a trend toward reduction in 30-day ischemic events.

Keywords

Coronary artery bypass grafting Clopidogrel Postoperative hemorrhage 

Notes

Acknowledgments

The CLARITY - TIMI 28 trial was supported by the pharmaceutical partnership of Sanofi-Aventis and Bristol-Myers Squibb.

References

  1. 1.
    Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, Maida R, Collins M, Kreps E, Moses J (1999) Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 99:2364–2366PubMedGoogle Scholar
  2. 2.
    Mishkel GJ, Aguirre FV, Ligon RW, Rocha-Singh KJ, Lucore CL (1999) Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol 34:1884–1890PubMedCrossRefGoogle Scholar
  3. 3.
    CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339CrossRefGoogle Scholar
  4. 4.
    CURE Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. NEJM 345:494–502CrossRefGoogle Scholar
  5. 5.
    Steinhubl SR, Berger PB, Mann JT, Fry ETA, Delago A, Wilmer C, Topol EJ (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411–2420PubMedCrossRefGoogle Scholar
  6. 6.
    Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montelescot G, Theroux P, Claeys M, Cools F, Hill K, Skene A, McCabe C, Braunwald E (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. NEJM 352:1179–1189PubMedCrossRefGoogle Scholar
  7. 7.
    COMMIT collaborative group (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621CrossRefGoogle Scholar
  8. 8.
    Chu MWA, Wilson SR, Novick RJ, Stitt LW, Quantz MA (2004) Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 78:1536–1541PubMedCrossRefGoogle Scholar
  9. 9.
    Hongo RH, Ley J, Dick SE, Yee RR (2002) The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. JACC 40:231–237PubMedGoogle Scholar
  10. 10.
    Kapetanakis EI, Medlam DA, Boyce SW, Haile E, Hill PC, Dullum MKC, Bafi AS, Petro KR, Corso PJ (2005) Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist’s panacea or the surgeon’s headache? Eur Heart J 26:576–583PubMedCrossRefGoogle Scholar
  11. 11.
    Ascione R, Ghosh A, Rogers CA, Cohen A, Monk C, Angelini GD (2005) In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg 79:1210–1216PubMedCrossRefGoogle Scholar
  12. 12.
    Cannon CP, Shamir MR, Aranki SF (2005) Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. Ann Thorac Surg 80:768–779PubMedCrossRefGoogle Scholar
  13. 13.
    Karabulut H, Toraman F, Evrenkaya S, Goksel O, Tarcan S, Alhan C (2004) Clopidogrel does not increase bleeding and allogenic blood transfusion in coronary artery surgery. Eur J Cardiothorac Surg 25:419–423PubMedCrossRefGoogle Scholar
  14. 14.
    Carpino PA, Bojar RM, Khabbaz KR, Rastegar H, Warner KG (2001) Clopidogrel therapy prior to coronary artery bypass surgery does not increase bleeding complications or use of blood products. (Abstract S120) Crit Care Med 29(Suppl):314Google Scholar
  15. 15.
    Sabatine MS, McCabe CH, Gibson CM, Cannon CP (2005) Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 trial. Am Heart J 149:227–233PubMedCrossRefGoogle Scholar
  16. 16.
    Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore J, Hillis D, Lambrew CT, Leigoff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH, for the TIMI Investigators (1991) Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction—results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II trial. Ann Intern Med 115:256–265Google Scholar
  17. 17.
    Cattaneo M (2004) Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24:1980–1987PubMedCrossRefGoogle Scholar
  18. 18.
    Wiviott SD, Antman EM (2004) Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 109:3064–3067PubMedCrossRefGoogle Scholar
  19. 19.
    Wang TH, Bhatt DL, Topol EJ (2005) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27:647–654PubMedCrossRefGoogle Scholar
  20. 20.
    Chen L, Bracey AW, Radovancevic R, Cooper JR, Collard CD, Vaughn WK, Nussmeier NA (2004) Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 128:425–431PubMedCrossRefGoogle Scholar
  21. 21.
    Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI—CLARITY study. JAMA 294:1224–1232PubMedCrossRefGoogle Scholar
  22. 22.
    Fox KAA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S (2004) Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation 110:1202–1208PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Dalton S. McLean
    • 1
  • Marc S. Sabatine
    • 1
  • Wei Guo
    • 2
  • Carolyn H. McCabe
    • 1
  • Christopher P. Cannon
    • 1
    Email author
  1. 1.Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  2. 2.Harvard Clinical Research InstituteBostonUSA

Personalised recommendations